Renaissance Capital logo

STOK News

June's flood of biotech IPOs continues with these 4 deals

BBIO

June is seeing a wave of biotech IPOs. Five priced last week, and four more are on the IPO calendar for this week.   Recent biotech IPOs have mostly underperformed, though 2 are up +100% ...read more

US IPO Weekly Recap: WORK's direct listing works as Slack and 6 others go public

WORK

Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public investors ended the week with losses. The stock closed Friday at $37.22, down 3.3% from the opening trade. With millions of users...read more

Genetic disease biotech Stoke Therapeutics prices upsized IPO above the range at $18

STOK

Stoke Therapeutics, a preclinical biotech developing RNA-targeted therapies for rare genetic diseases, raised $142 million by offering 7.9 million shares at $18, above the range of $14 to $16. The company had previously filed to offer 6.7 million shares. Stoke Therapeutics plans to list on the Nasdaq under the symbol STOK. J.P. Morgan, Cowen and Credit Suisse acted as joint...read more

June is getting a flood of biotech IPOs with these 9 deals on the calendar

ADPT

A wave of biotechs are preparing to go public in June, with five on the IPO calendar for this week and four more scheduled for the week of June 24. Two others could soon launch June/July IPOs as well. Recent biotech IPOs have mostly underperformed, though 2 are up +100% ...read more